Evaluation of pulmonary side effects in prolactinoma patients treated with cabergoline

Sadeleştirilmiş öğe sayfası
dc.contributor.authorSoyluk, Ozlem
dc.contributor.authorBingol, Zuleyha
dc.contributor.authorCiftci, Sema
dc.contributor.authorKurtulmus, Neslihan
dc.contributor.authorTanrikulu, Seher
dc.contributor.authorYarman, Sema
dc.date.accessioned2025-10-16T15:14:56Z
dc.date.issued2023
dc.identifier.doi10.5603/EP.a2023.0045
dc.identifier.otherWOS:001050080100001
dc.identifier.urihttps://openaccess.acibadem.edu.tr/handle/11443/6322
dc.publisherVIA MEDICA
dc.sourceENDOKRYNOLOGIA POLSKA
dc.subjectpleural fibrosis
dc.subjectpulmonary fibrosis
dc.subjectdopamine agonist
dc.subjectprolactinoma
dc.subjectcabergoline
dc.titleEvaluation of pulmonary side effects in prolactinoma patients treated with cabergoline
dc.typeArticle

Dosyalar

Koleksiyonlar

WOS